Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.00 (0.00%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £8.08m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Director Dealing

19 Dec 2018 18:28

RNS Number : 0427L
Renalytix AI PLC
19 December 2018
Β 

Β 

Renalytix AI plc

Β 

("RenalytixAI" or the "Company")Β 

Β 

Β 

Director Dealing

Β 

Β 

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 5,970 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 103 pence per share.

Β 

Following this purchase, Mr Mills is interested in 9,196,400 Ordinary Shares representing 17.09% of the total voting rights in the Company.

Β 

Enquiries:

Β 

Renalytix AI plc

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR or

Tel: +1 646 397 3970

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)

Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited

Tel: 020 7933 8780

or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

Β 

Β 

Β 

Β 

Β 

Β 

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Β 

Harwood Capital LLP (Harwood) as investment manager to NASCIT

Β 

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Β 

Christopher Mills, non-executive director of the issuer and director of North Altantic Smaller Companies Investment Trust plc (NASCIT)

b)

Β 

Initial notification /Amendment

Β 

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Β 

Renalytix AI Plc

b)

Β 

LEI

Β 

Β 

213800NTOH3FK3WER551

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

Β 

a)

Β 

Description of the financial instrument, type of instrument

Ordinary shares of 0.25 pence each

Β 

Identification code

GB00BYWL4Y04

Β 

b)

Β 

Nature of the transaction

Β 

Β 

Purchase of shares

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Β 

Β 

Price(s)

Volume(s)

Β 

Β 

103 pence

5,970

Β 

Β 

Β 

Β 

Β 

d)

Β 

Aggregated information

N/A

- Aggregated volume

- Price

e)

Β 

Date of the transaction

Β 

Β 

19 December 2018

f)

Β 

Place of the transaction

Β 

Β 

London Stock Exchange

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHFKCDBFBDDQBD
Date   Source Headline
30th Oct 20254:58 pmRNSHolding(s) in Company
28th Oct 20254:04 pmRNSHolding(s) in Company
27th Oct 20257:00 amRNSConfirmation of receipt of £860k R&D tax credits
24th Oct 202510:12 amRNSHolding(s) in Company
23rd Oct 20259:09 amRNSHolding(s) in Company
21st Oct 202510:08 amRNSHolding(s) in Company
17th Oct 202510:26 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSHolding(s) in Company
16th Oct 20252:31 pmRNSHolding(s) in Company
16th Oct 202512:15 pmRNSHolding(s) in Company
15th Oct 20259:48 amRNSHolding(s) in Company
10th Oct 20252:34 pmRNSHolding(s) in Company
10th Oct 20259:56 amRNSHolding(s) in Company
10th Oct 20257:01 amRNSHolding(s) in Company
10th Oct 20257:00 amRNS$4m balance sheet improvement with bond conversion
9th Oct 20254:43 pmRNSHolding(s) in Company
7th Oct 20253:03 pmRNSHolding(s) in Company
3rd Oct 20252:32 pmRNSHolding(s) in Company
2nd Oct 20252:57 pmRNSHolding(s) in Company
1st Oct 20252:43 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
1st Oct 20257:00 amRNSCE Mark application submission
30th Sep 20254:02 pmRNSHolding(s) in Company
29th Sep 20255:18 pmRNSHolding(s) in Company
29th Sep 20252:28 pmRNSHolding(s) in Company
29th Sep 20259:32 amRNSHolding(s) in Company
29th Sep 20257:00 amRNSHolding(s) in Company
26th Sep 202512:17 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNS£7.05m total gross proceeds from Fundraise
24th Sep 20252:00 pmRNSUpdate Regarding Forward Guidance
24th Sep 202510:00 amRNSAdditional Subscription for 11m Shares
23rd Sep 20257:00 amRNSInvestor Presentation and Revised Revenue Guidance
22nd Sep 20255:30 pmRNSResult of Fundraise
22nd Sep 20257:01 amRNSWRAP Retail Offer for up to £500,000
22nd Sep 20257:00 amRNSProposed Fundraise
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20256:26 pmRNSHolding(s) in Company
16th Sep 20257:00 amRNSHolding(s) in Company
15th Sep 20257:00 amRNSTempus AI Inc, collaboration agreement
11th Sep 20255:14 pmRNSHolding(s) in Company
10th Sep 20254:32 pmRNSHolding(s) in Company
2nd Sep 202512:46 pmRNSHolding(s) in Company
1st Sep 202511:18 amRNSHolding(s) in Company
29th Aug 20259:25 amRNSHolding(s) in Company
26th Aug 202511:45 amRNSHolding(s) in Company
22nd Aug 20255:11 pmRNSHolding(s) in Company
22nd Aug 20251:30 pmRNSHolding(s) in Company
29th Jul 20257:00 amRNSServices contract with Joslin and Pharma Partner
17th Jul 20257:01 amRNSPartnership with MVP Health Care
17th Jul 20257:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.